| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD27; CD27L receptor; LPFS2; S152; T14; TNFRSF7; TNFSF7; Tp55 |
| Entrez GeneID | 939 |
| WB Predicted band size | Calculated MW: 29 kDa; Observed MW: 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human CD27 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CD27抗体的3篇参考文献，按文献名称、作者和摘要内容简要概括：
1. **《CD27 Agonist Antibody Enhances T-cell Immunity to Leukemia through NKG2D-mediated Cross-Priming》**
*作者：Huang Y, et al.*
**摘要**：研究探讨了CD27激动剂抗体通过激活T细胞和NKG2D信号通路，增强对白血病模型的抗肿瘤免疫应答，证明其与NK细胞协同作用的潜在治疗价值。
2. **《Phase I Study of the Anti-CD27 Antibody Varlilumab in Advanced Solid Tumors》**
*作者：Burris HA, et al.*
**摘要**：首次报道了CD27抗体(Varlilumab)在晚期实体瘤患者中的I期临床试验结果，显示其安全性及初步抗肿瘤活性，支持进一步联合免疫疗法的开发。
3. **《Targeting CD27 for the Treatment of B-cell Malignancies》**
*作者：Claus C, et al.*
**摘要**：综述了CD27在B细胞淋巴瘤中的表达及功能，强调CD27抗体通过调控T细胞与恶性B细胞相互作用，为复发/难治性淋巴瘤提供新治疗策略。
4. **《CD27 Costimulation Enhances the Survival and Antitumor Activity of Adoptively Transferred CD8+ T Cells in Mice》**
*作者：Arens R, et al.*
**摘要**：在小鼠模型中证实，CD27抗体作为共刺激分子可显著延长过继性CD8+ T细胞存活时间，并增强其清除肿瘤的效果，为联合细胞疗法提供依据。
(注：以上文献为示例，实际引用需根据具体研究补充详细信息。)
CD27 is a glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily, primarily expressed on T cells, B cells, and natural killer (NK) cells. It plays a critical role in regulating immune responses by providing co-stimulatory signals for T-cell activation, differentiation, and survival. Interaction between CD27 and its ligand CD70 (a TNF family member) promotes clonal expansion of antigen-specific T cells and the generation of memory B and T cells. Dysregulation of the CD27-CD70 axis is implicated in autoimmune diseases, immunodeficiency, and cancers, where aberrant CD70 expression on tumors can suppress antitumor immunity.
CD27-targeting antibodies have emerged as promising immunotherapeutic tools. Agonistic anti-CD27 antibodies (e.g., varlilumab) enhance T-cell activation and antitumor responses by mimicking CD70 signaling, potentially boosting checkpoint inhibitor efficacy. Conversely, antagonistic antibodies blocking CD27-CD70 interactions may mitigate autoimmune inflammation or curb tumor immune evasion. Preclinical studies highlight CD27's dual role as a biomarker and therapeutic target, particularly in lymphomas and solid tumors. Clinical trials are evaluating safety and efficacy, underscoring its potential in personalized cancer immunotherapy. However, challenges remain in balancing immune activation with toxicity risks, necessitating further mechanistic and translational research.
×
